In a surprising move, Ohio is set to eliminate the Ohio Board of Pharmacy’s (BoP) regulation over office-based opioid treatment (OBOT) clinics. Ohio law currently prescribes that any clinic providing treatment for opioid dependence or addiction to more than 30 individuals, using a controlled substance like Suboxone or Subutex, must possess a Terminal Distributor of Dangerous Drugs (TDDD) license with an OBOT classification.
Ohio’s House Bill 33 of the 135th General Assembly, colloquially known as the Operating, proposes this significant change in the state’s opioid regulation mechanism, according to a report by Dinsmore & Shohl LLP.
The upcoming deregulation prompts several questions for legal professionals, particularly regarding oversight mechanisms and frameworks for effectively regulating these OBOT clinics. It furthermore casts a spotlight on the overall efficacy of such regulatory structures in managing the opioid crisis, indicating the need for comprehensive, strategic legal frameworks that incorporate not only the supply but also the demand side of drug use and misuse.
Given the global relevance of the opioid crisis, how Ohio navigates the complex regulatory requirements that this situation necessitates may, in turn, influence opioid regulatory approaches and legislation in other jurisdictions. Therefore, legal professionals should monitor this situation closely for its wider implications in terms of regulatory precedents, practice standards, and potential legal ramifications.